Summary The objectives of this study were to better our understanding of the carcinogenesis of gestational trophoblastic tumours and to investigate the possible presence of mutational alteration of the p53 tumoursuppressor gene in these tumours. Amplification-based direct DNA sequencing was performed on 14 hydatidiform moles, six invasive moles, eight choriocarcinomas and ten normal early placental tissues. No mutation in exons 5-8 was detected in any of these 38 tissue specimens. These results suggest that a mutation in p53 tumour suppressor either does not exist or is a very rare event in gestational trophoblastic tumours. The gestational trophoblastic tumours probably involve a tumour-suppressor gene other than p53 gene or may follow a completely different pathway to their malignant phenotype.
Gestational trophoblastic diseases are a group of clinically and histopathologically defined entities with characteristics of reproductive failure and a high neoplastic potential (Roberts and Mutter, 1994) . Major advances have been achieved during the past 40 years in the epidemiology, aetiology, pathology, endocrinology, immunology, diagnosis and treatment of gestational trophoblastic disease (Lurain, 1990) . Early diagnosis and effective treatment of patients with gestational trophoblastic disease have resulted in almost 100% cure rates in non-metastatic disease and in the majority of patients with metastases (Lurain, 1990) .
However, there is so far no reliable genetic marker for predicting which subset of moles will behave aggressively. For the most part, the pathogenesis and aetiology for hydatidiform mole and choriocarcinoma are still considered by many as controversial and unclear. Mutation of the p53 gene, which encodes a nuclear phosphoprotein of 393 amino acids, is the most common genetic alteration in human cancers (Greenblatt et al., 1994) . The p53 protein functions as tumour suppressor, which negatively regulates cell growth. Numerous recent reports have shown that missense or frameshift mutations of the p53 gene can be found in almost every type of tumour (Greenblatt et al., 1994; Berchuck et al., 1994) suggesting aberrations of possible common pathways of growth control in these diverse malignancies. Although mutations in the p53 gene have been identified throughout the gene, the vast majority (over 98%) of them locate in exons 5-8 regardless of the tumour type.
To evaluate the frequency of p53 mutation in the gestational trophoblastic tumours, we describe here the use of the polymerase chain reaction (PCR)-based direct DNA sequencing method to examine the DNA sequences of exons 5-8 of the p53 gene in 28 gestational trophoblastic tumours and in ten normal early placental tissues. Using this approach, no mutations were found in either the tumour or the normal placental tissues.
Materials and methods Materials
Serial 4 -5 gm sections of paraffin-embedded tissues were prepared from 14 hydatidiform moles, six invasive moles, eight choriocarcinomas and ten normal early placental tissues (Table I 8 (Chang et al., 1992) .
Immunohistochemical staining of p53 protein in trophoblastic tissues
Sections (4 jgm) of formalin-fixed, paraffin-embedded tissues were cut. Sections were then deparaffinised, rehydrated and stained using the avidin-biotin-peroxidase complex method. Both anti-p53 antibody (clone DO-7) and conjugated secondary antibody (rabbit anti-mouse horseradish peroxidase) were obtained from Dako (Copenhagen). p53 staining results were scored by a modified version of Fromwitz's method with a combined tally for intensity of stained p53 signal and percentage of cells stained positive for p53 (Fromwitz et al., 1987) . Intensity of stained p53 signal was scored 3, 2, 1 and 0 representing strong, moderate, weak and negative signals respectively. The percentage of cells stained positive for p53 was also scored 3, 2, 1 and 0 representing >75%, 50 -75%, 25 -50% and <25% cells stained positive for p53 respectively. Therefore, the highest and lowest possible scores are 6 and 0 respectively. The Fromwitz scores were determined by C-L Z, who is a pathologist and had prior knowledge of the histopathological findings at the time of scoring. , 1990) . The sequence information for the primers is listed in Table II . The conditions used for the amplification reactions have been described earlier (Pao et al., 1994) with minor modifications. Briefly, approximately 0.5,ug of purified cellular DNA was amplified with thermostable Taq DNA polymerase in a Thermal Cycler (Model 480, PerkinElmer Cetus, Norwalk, CT, USA). The 50 ,ul amplification reaction mixture contained 10 mmol 1-l Tris-HCl, pH 8.3, 50 mmol 1-l potassium chloride; 1.5 mmol 1-l magnesium chloride; 0.01% gelatin; 10 pmole each of the primers for the initial amplification; 2.5 nmol each of the four deoxyribonucleoside triphosphates and 1 unit of Taq DNA polymerase (Perkin-Elmer Cetus). Amplification reactions were cycled 45 times beginning with 94°C for 30 s to denature the target DNA. This process was then followed by re-naturation for 30s at either 550C or 60°C, depending on the exons being amplified and primers used for most efficient amplification. All extension reactions were carried out at 72°C for 60 s. The amplified DNA products were confirmed by agarose gel electrophoresis. Because of the sensitivity of the PCR, a number of precautions were taken to minimise the possibility of contamination during sampling and subsequent processing (Pao et al., 1991 (Pao et al., , 1993 (Pao et al., , 1994 .
DNA sequencing analysis Aliquots of 5 ,l of each of the five sets of the amplification products were used to generate single-stranded DNA for subsequent direct sequencing of each exon of the p53 gene. Two asymmetric amplification reactions, one each with an excess of one of the primers over the other of opposite orientation, were performed in order to sequence from both directions. The single-stranded DNA was purified by repeated alcohol precipitation and washing. The resuspended DNA was then subjected to direct DNA sequencing using a Sequenase version 2. Figure 2 . Exon 5 of the p53 gene was amplified and sequenced in two parts for greatest efficiency. The DNA sequencing results of the p53 gene confirmed that no mutation could be found in exons 5, 6, 7 and 8 of any of the 38 tissues studied (data not shown).
Discussion
We have screened exons 5 -8 of the p53 genes of 14 hydatidiform moles, six invasive moles, eight choriocarcinoma and ten normal early placental tissues by PCR amplification followed by direct DNA sequencing for the possible presence of genetic aberrations. Our research does not reveal any DNA sequence alteration in any of these 38 tissues. The regions of p53 genes we have examined include exons that are known for their functional importance (Ullrich et al., 1992) . The overwhelming majority (over 98%) of p53 gene mutations in tumour tissues and cancer cell lines reported so far in the literature are clustered within exons 5-8, equivalent to amino acid residues 130 and 290 of p53 protein (Hollstein et al., 1991; Levine et al., 1991) . This is also a region where the DNA sequences are highly conserved among several different species (Soussi et al., 1990; Pao et al., Figure 2 Agarose gel electrophoresis of PCR amplification products of p53 gene DNA sequences. Plasmid pGEM-3 DNA digested with a mixture of three restriction endonucleases (Hinfl, RsaI and SinI) was used as DNA size markers in the two outside lanes (lanes M), and the sizes of these DNA fragments are (from top to bottom) 2645, 1605, 1198, 676, 517, 460, 396, 350, 222, 179, 126, 75, 65, 51 and 36bp . Lanes A and B are DNA from upstream and downstream portions of exon 5 of the p53 gene respectively. The amplified DNA are 129 and 127 base pairs respectively. Lanes C, D and E are DNA for exons 6, 7 and 8 respectively and their sizes are 130, 118 and 141 bp respectively. 1994). In order to include any possible mutation that may occur at the intron-exon splicing junction, we chose to amplify the individual exon DNAs instead of amplifying the complete cDNA fragment in one single piece. It is, therefore, relatively safe to assume that we probably would have detected p53 mutations if they did exist.
There seems to be a trend between the Fromwitz score and the histological findings in the tissue specimens. However, p53 overexpression, as indicated by immunohistochemical staining, could be the result of actively proliferating cells and not necessarily due to the presence of a mutant form of p53 protein. This notion was supported by the observations of p53 overexpression in inflammatory lesions (Bosari et al., 1993) , and in the basal layers of warts and in the basal to middle third of cervical intraepithelial neoplasia lesions (Cooper et al., 1993) . Therefore, it would not be inconsistent to state that increased p53 expression correlates with histological type and that p53 mutations were not observed. Whether this is really the case would have to be examined further.
Genetic mutation in tumour-suppressor gene p53 is thought to contribute to tumour growth by inactivating proteins that normally act to limit cell proliferation (Ullrich et al., 1992) . A central role for p53 gene in transcription and phosphorylation events required for passage of a cell from GI to S-phase and in the decision of a cell to replicate or to go to apoptosis has become apparent (Levine et al., 1994 proposed that the p53 gene (or the mutant form of the p53 gene) is either not important or not directly involved in the oncogenesis of gestational trophoblastic tumours.
The complete lack of mutations in the p53 gene in cancers or in conditions related to cancer susceptibility are quite rare and have been reported only in paediatric astrocytomas (Litofsky et al., 1994) , malignant melanoma (Castresana et al., 1993) and testicular cancer (Fleischhacker et al., 1994) . The reason for and significance of our failing to detect p53 genetic aberrations in gestational trophoblastic tumours are not completely clear at the present time. It is possible that some of these tumours contain mutations located outside the regions of p53, that we and others (Cheung et al., 1993; Chen et al., 1994) have examined. However, this prospect is not very likely because it would suggest involvement of regions of p53 proteins that are either not known to contain frequent mutations in cancers or to be considered functionally important. Another possibility is that there are other tumour-suppressor genes whose inactivation or loss of function is important in the carcinogenesis of these tumours, as has been suggested (Miyamoto et al., 1991) . Furthermore, it is also possible that carcinogenesis of gestational trophoblastic tumours, or at least certain subsets of them, may follow a completely different pathway to their malignant phenotype, such as telomere length and telomerase activity (Kim et al., 1994; Wynford-Thomas et al., 1995) . The notion that most, if not all, gestational trophoblastic tumours contain only the wild-type p53 gene and that these tumours may arise through a transformation process other than genetic alteration of the p53 gene, is compatible with the fact that these tumours have an excellent (90-100%) chemotherapy cure rate. The link between the lack of a p53 mutation and the inherent high sensitivity to chemotherapy of gestational trophoblastic tumours is underscored by recent reports that loss of p53 function may reduce the response of malignant tumours to treatment (El Rouby et al., 1993; Harris et al., 1993) .
In summary, the results of this study indicate that the gestational trophoblastic tumours either do not contain or very rarely contain genetic alterations in the functional important domains of the p53 tumour-suppressor gene. p53 gene may not play an important role in the carcinogenesis of these tumours. More studies are needed to better define the aetiology of gestational trophoblastic tumours.
